We Offer Worldwide Shipping
Login Wishlist

Ebracteolata cpd B

$230

Brand : BIOFRON
Catalogue Number : AV-B04117
Specification : 98%
CAS number : 83459-37-4
Formula : C10H12O4
Molecular Weight : 196.2
PUBCHEM ID : 902138
Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

AV-B04117

Analysis Method

HPLC,NMR,MS

Specification

98%

Storage

2-8°C

Molecular Weight

196.2

Appearance

Powder

Botanical Source

Structure Type

Phenols

Category

Standards;Natural Pytochemical;API

SMILES

CC1=C(C(=C(C=C1O)OC)C(=O)C)O

Synonyms

1-(2,4-Dihydroxy-6-methoxy-3-methylphenyl)ethanone/2,4-Dihydroxy-6-methoxy-3-methylacetophenone/Ethanone, 1-(2,4-dihydroxy-6-methoxy-3-methylphenyl)-/1-(2,4-Dihydroxy-6-methoxy-3-methyl-phenyl)-aethanon/1-(2,4-dihydroxy-6-methoxy-3-methyl-phenyl)-ethanone

IUPAC Name

1-(2,4-dihydroxy-6-methoxy-3-methylphenyl)ethanone

Density

1.2±0.1 g/cm3

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

141.5±15.8 °C

Boiling Point

355.5±22.0 °C at 760 mmHg

Melting Point

224℃

InChl

InChI=1S/C10H12O4/c1-5-7(12)4-8(14-3)9(6(2)11)10(5)13/h4,12-13H,1-3H3

InChl Key

RFKMWWMZUHXFBA-UHFFFAOYSA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:83459-37-4) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29641749

Abstract

Objective
Staphylococcus aureus strains can be disseminated during dental treatments and occasionally lead to the contamination and infection of patients and dentists, which is an important public health problem. The dynamics of the airborne propagation and the genetic diversity of S. aureus isolated in an academic dental clinic environment were investigated using isoenzyme typing.

Material and Methods
The isoenzymes of 44 previously reported isolates were obtained from fresh cultures and extracted using glass beads. Nine isoenzymes were investigated using multilocus enzyme electrophoresis (MLEE). The genetic diversity and relationship among the strains (electrophoretic type – ET) were determined using statistics previously described by Nei 25 (1972) and the SAHN grouping method (UPGMA algorithm).

Results
Clonal pattern analyses indicated a high level of genetic polymorphism occurring among the 33 ETs, which were grouped into five taxa. Each taxon presented one or more clusters that were moderately related and that contained two or more identical/highly related isolates, revealing seasonal airborne propagation in these dental clinic environments.

Conclusions
These data suggest the occurrence of active microevolutionary processes in S. aureus as well as the possibility of environmental propagation during a 14-month time span. Such findings are important to show that multiuser academic dental clinics can retain certain strains that are spreadable to different niches.

KEYWORDS

Staphylococcus aureus, Dentistry, Environment, Molecular biology, Genetic diversity

Title

Dynamics of the seasonal airborne propagation of Staphylococcus aureus in academic dental clinics

Author

Wagner Luiz de Carvalho Bernardo, 1 Jeferson J?nior da Silva, 1 , 2 Jose Francisco Hofling, 1 Edvaldo Ant?nio Ribeiro Rosa, 3 and Marcelo Fabiano Gomes Boriollo 1 , 2

Publish date

2018;

PMID

32206157

Abstract

Background
Cell-free circulating tumour DNA blood testing (also called liquid biopsy) can determine if a person with advanced non-small cell lung cancer (NSCLC) whose disease is progressing has developed the epidermal growth factor receptor (EGFR) T790M resistance mutation. Identifying this resistance mutation can help physicians choose appropriate treatment (i.e., osimertinib if positive and chemotherapy if negative). Tissue biopsy is typically used to look for the resistance mutation, but this is an invasive test that might not be feasible if the patient is too ill. We conducted a health technology assessment of liquid biopsy for people with advanced NSCLC, which included an evaluation of the diagnostic accuracy, clinical utility, safety, cost-effectiveness, and the budget impact of publicly funding liquid biopsy, as well as an evaluation of patient preferences and values.

Methods
We performed a systematic literature search of the clinical evidence. We assessed the risk of bias of each included study using Risk of Bias in Systematic Reviews (ROBIS), Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2), Risk of Bias Among Non-randomized Studies (RoBANS), and the Cochrane risk of bias (ROB) tool and assessed quality of evidence according to the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) Working Group criteria. We performed a systematic economic literature search and conducted short-term and long-term cost-effectiveness and cost-utility analyses comparing liquid biopsy as a triage test, liquid biopsy alone, and tissue biopsy alone from a public payer perspective. We also analyzed the budget impact of publicly funding liquid biopsy for people in Ontario with advanced NSCLC. To assess the potential value of liquid biopsy, we spoke with people with lung cancer and people with an understanding of the process of liquid biopsy.

Results
We included 19 studies (within a published systematic review) to examine diagnostic test accuracy and 12 studies to examine clinical utility. In patients with advanced NSCLC, liquid biopsy to detect the EGFR T790M resistance mutation demonstrated a positive and negative predictive value of 89% and 61%, respectively, a sensitivity of 68%, and specificity of 86%. No studies examined the clinical utility of liquid biopsy as a triage test. When NSCLC was treated appropriately, progression-free survival was similar in patients with and without the resistance mutation, as ascertained by liquid biopsy.

We estimated that it costs about $700 to conduct a liquid biopsy and $2,500 to conduct a tissue biopsy. Our analyses showed that, when considering costs and effects directly related to testing, liquid biopsy (as a triage test, which means patients who test negative undergo a follow-up tissue biopsy, or alone, which means using only liquid biopsy) was less costly than tissue biopsy alone and led to fewer tissue biopsies. Using liquid biopsy as a triage test produced the most correct treatment decisions and greatest number of people who were given osimertinib.

When considering long-term costs (i.e., treatment and care) and effects (i.e., life-years and quality-adjusted life-years [QALYs]), liquid biopsy as a triage test was the most effective and most costly strategy followed by liquid biopsy alone. Tissue biopsy alone was the least effective and least costly strategy. The incremental cost-effectiveness ratios (ICERs) of liquid biopsy as a triage test compared with liquid biopsy alone and of liquid biopsy alone compared with tissue biopsy alone were greater than $100,000 per QALY. However, this result was largely driven by the cost of osimertinib, which was used more often when liquid biopsy was used as a triage test.

We estimated that the total annual budget impact of publicly funding liquid biopsy as a triage test in Ontario over the next 5 years would range from approximateily $60,000 in year 1 to $3 million in year 5.

People with lung cancer with whom we spoke said that liquid biopsy would likely be an appropriate test for people with NSCLC given their frail condition and because it would avoid the pain and anxiety associated with tissue biopsy.

Conclusions
As a minimally invasive test, liquid biopsy identifies a high proportion of people with the EGFR T790M resistance mutation. This identification could better guide treatment for people with advanced NSCLC. However, its relatively low negative predictive value means it is best used as a triage test (i.e., followed by tissue biopsy if the liquid biopsy does not identify a resistance mutation). Liquid biopsy as a triage test is likely more effective than tissue biopsy alone. However, owing to the high cost of treatment, liquid biopsy may not be cost-effective. We estimated that publicly funding liquid biopsy as a triage test in Ontario would result in additional costs (related to more patients being treated) of between $0.06 million and $3 million over the next 5 years.

Title

Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment

Author

Ontario Health (Quality)

Publish date

2020;

PMID

26594571

Abstract

In the title compound, C21H22ClNO3, the penta­diene unit is nearly planar [maximum deviation = 0.023?(1)?a], but the carbonyl O atom deviates significantly [by 0.304?(1)?a] from its mean plane, which is twisted with respect to the phenyl and chloro­benzene rings by 71.34?(13) and 46.40?(13)°, respectively. In the crystal, inversion-related molecules are linked by two pairs of O?H?O hydrogen bonds, forming chains propagating along [01-1], enclosing R 2 2(16) and R 2 2(22) ring motifs. The chains are linked via C?H?O hydrogen bonds and C?H?π inter­actions into a three-dimensional supra­molecular architecture.

KEYWORDS

crystal structure, dienes, enamines, hydrogen bonding, C?H?π inter­actions

Title

Crystal structure of (2E,4E)-5-[bis­(2-hy­droxy­eth­yl)amino]-1-(4-chloro­phen­yl)-5-phenyl­penta-2,4-dien-1-one

Author

Alexander A. Golovanov,a Anna V. Vologzhanina,b Ivan S. Odin,a Tat’yana P. Tret’yakova,c and Sergey V. Naumovc,

Publish date

2015 Nov 1